Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma

Clinical trial NCT07501104 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07501104
Sponsor: Shanghai Zhongshan Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Melanoma (Skin Cancer)

Start date: 2026-05-01
Primary completion: 2029-09-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.